These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 7939768)
1. Porcine factor VIII therapy in patients with congenital hemophilia and inhibitors: efficacy, patient selection, and side effects. Hay CR; Lozier JN; Lee CA; Lafan M; Tradati H; Santagostino E; Ciavarella N; Schiavoni M; Fukui H; Yoshioka A Semin Hematol; 1994 Apr; 31(2 Suppl 4):20-5. PubMed ID: 7939768 [No Abstract] [Full Text] [Related]
2. Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey. Hay CR; Lozier JN; Lee CA; Laffan M; Tradati F; Santagostino E; Ciavarella N; Schiavoni M; Fukui H; Yoshioka A; Teitel J; Mannucci PM; Kasper CK Thromb Haemost; 1996 Jan; 75(1):25-9. PubMed ID: 8713775 [TBL] [Abstract][Full Text] [Related]
3. Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors. Lozier JN; Santagostino E; Kasper CK; Teitel JM; Hay CR Semin Hematol; 1993 Apr; 30(2 Suppl 1):10-21. PubMed ID: 8480192 [TBL] [Abstract][Full Text] [Related]
4. The use of porcine factor VIII in Japan. Yoshioka A; Shima M; Morichika S; Terada S; Fukui H Semin Hematol; 1994 Apr; 31(2 Suppl 4):26-8. PubMed ID: 7939769 [No Abstract] [Full Text] [Related]
5. The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group. Kessler CM; Ludlam CA Semin Hematol; 1993 Apr; 30(2 Suppl 1):22-7. PubMed ID: 8480193 [No Abstract] [Full Text] [Related]
6. The development and characterisation of antibodies to human factor VIII in haemophilic dogs. Littlewood JD; Barrowcliffe TW Thromb Haemost; 1987 Jun; 57(3):314-21. PubMed ID: 3116702 [TBL] [Abstract][Full Text] [Related]
7. [Poly-electrolyte fractionated porcine factor VIII in the treatment of hemophilia A]. Ferencz T; Skopál J; Csáki C; Laczkó M; Schuler D; Borsi J Orv Hetil; 1993 Dec; 134(52):2873-5. PubMed ID: 8272354 [TBL] [Abstract][Full Text] [Related]
9. [Porcine factor VIII]. De Juan MJ; Montoro JB; Tusell JM Sangre (Barc); 1991 Jun; 36(3):217-20. PubMed ID: 1948542 [No Abstract] [Full Text] [Related]
10. [Side-effects of factor VIII substitution in patients with hemophilia A (author's transl)]. Tilsner V; Reuter H MMW Munch Med Wochenschr; 1982 Jun; 124(22):553-7. PubMed ID: 6808385 [No Abstract] [Full Text] [Related]
11. The use of porcine factor VIII in France. Negrier C Semin Hematol; 1994 Apr; 31(2 Suppl 4):29-32. PubMed ID: 7939770 [No Abstract] [Full Text] [Related]
12. Suppression of factor VIII antibody by combined factor VIII and cyclophosphamide. Nilsson IM; Hedner U; Holmberg L Acta Med Scand; 1974; 195(1-2):64-72. PubMed ID: 4817094 [No Abstract] [Full Text] [Related]
13. [Comparison of anti-human and anti-porcine factor VIII antibody titers in patients with hemophilia]. Windyga J; Rzymkiewicz L; Lopaciuk S Acta Haematol Pol; 1996; 27(1):27-31. PubMed ID: 8629440 [TBL] [Abstract][Full Text] [Related]
14. Hemophilia. Strategies for the treatment of inhibitor patients. Ingerslev J Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863 [TBL] [Abstract][Full Text] [Related]
15. Induction of tolerance using porcine factor VIII. Hay CR; Laurian Y Vox Sang; 1996; 70 Suppl 1():68-9. PubMed ID: 8869473 [No Abstract] [Full Text] [Related]
17. Porcine factor VIII: preparation and use in treatment of inhibitor patients. Kernoff PB Prog Clin Biol Res; 1984; 150():207-24. PubMed ID: 6431429 [No Abstract] [Full Text] [Related]
18. The clinical use of porcine factor VIII. Kernoff PB Prog Clin Biol Res; 1990; 324():47-56. PubMed ID: 2106692 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil. Rieger A; Roisenberg I Thromb Haemost; 1999 Mar; 81(3):475-6. PubMed ID: 10102489 [No Abstract] [Full Text] [Related]
20. [Lymphocyte T population in hemophilia A and its relation with factor VIII therapy and the presence of HBsAg or anti-F.VIII:C inhibitors]. Aznar JA; Carbonell F; Jorquera JI; Carmona E; Sánchez-Cuenca JM; Trénor A; de Andrés-Medina R; González-Molina A Sangre (Barc); 1985; 30(5):821-30. PubMed ID: 3937253 [No Abstract] [Full Text] [Related] [Next] [New Search]